-
Analysis and Clinical Relevance of Tumor Mutational Burden
Tumor mutational burden (TMB) is a genomic biomarker. In contrast to other biomarkers that are detected as a genomic alteration in a specific gene or via methods like immunohistochemistry, TMB is calculated. However, disagreements about calculation method, clinical indication for immunotherapy, and other factors have hindered establishment of TMB as a standardized biomarker.
-
Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)
-
Determination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide
-
Webinar: IVDR in the laboratory routine – how to make the transition successfully?
Join us for our webinar on the European In Vitro Diagnostics Regulation (IVDR) on Thursday, May 25 at 17:00 CEST.
-
MH Guide 6.0: Next-level automation and precision in the clinical interpretation of cancer genomic profiling
Molecular Health has launched the latest version of its tertiary analysis solution for genomic profiling featuring improved variant classification and more targeted clinical trial matching.